Sarcoidosis Global Market 2016 Analysis and Forecast to 2021

PUNE, INDIA, November 11, 2016 /EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for Sarcoidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sarcoidosis and features dormant and discontinued projects.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/393594-sarcoidosis-pipeline-review-h1-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
- The report provides a snapshot of the global therapeutic landscape of Sarcoidosis
- The report reviews pipeline therapeutics for Sarcoidosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Sarcoidosis therapeutics and enlists all their major and minor projects
- The report assesses Sarcoidosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Sarcoidosis

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sarcoidosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sarcoidosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Sarcoidosis Overview 6
Therapeutics Development 7
Pipeline Products for Sarcoidosis - Overview 7
Sarcoidosis - Therapeutics under Development by Companies 8
Sarcoidosis - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Sarcoidosis - Products under Development by Companies 11
Sarcoidosis - Companies Involved in Therapeutics Development 12
Araim Pharmaceuticals, Inc. 12
FirstString Research, Inc. 13
PharmaIN Corporation 14
Sarcoidosis - Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Target 16
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
ABS-11 - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
cibinetide - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
eprodisate disodium - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Synthetic Peptide for Immunology, Cardiovascular Diseases, Respiratory Diseases and Female Sexual Dysfunction - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30

Access Report @ https://www.wiseguyreports.com/reports/393594-sarcoidosis-pipeline-review-h1-2016


Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here